Large gap with delayed quotes
|
Last quote
11/04/2025
-
02:00:00
|
Bid
11/04/2025 -
10:53:14
|
Bid Volume |
Ask
11/04/2025 -
10:53:14
|
Ask Volume |
|---|---|---|---|---|
|
12.23
-0.58
(
-4.53% )
|
10.98
|
100 |
13.61
|
100 |
Analysis date: 31.10.2025
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 31.10.2025.
Interest
None
None
No stars since 31.10.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 31.10.2025 at a price of 12.81.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 31.10.2025.
4wk Rel Perf
-3.12%
-3.12%
The four-week dividend-adjusted underperformance versus SP500 is 3.12%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.02%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.98%.
Mkt Cap in $bn
1.43
1.43
With a market capitalization <$2bn, NOVOCURE is considered a small-cap stock.
G/PE Ratio
0.08
0.08
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
-10.44
-10.44
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
0.83%
0.83%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
7
7
Over the last seven weeks, an average of 7 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
80
80
For 1% of index variation, the stock varies on average by 0.80%.
Correlation
0.20
0.20
Stock movements are totally independent of index variations.
Value at Risk
7.16
7.16
The value at risk is estimated at USD 7.16. The risk is therefore 55.92%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
08.01.2019
08.01.2019